Core Insights - Astellas Pharma is set to present significant clinical data at the ESMO congress, showcasing advancements in its oncology programs, particularly in muscle-invasive bladder cancer and hormone-sensitive prostate cancer [1][2][3] Astellas' Oncology Programs - The company will present ten abstracts, including new data for PADCEV (enfortumab vedotin) combined with pembrolizumab in muscle-invasive bladder cancer, which will be featured in an ESMO Presidential Symposium [1][2] - Final overall survival data for XTANDI (enzalutamide) in high-risk, biochemically recurrent non-metastatic hormone-sensitive prostate cancer will also be shared [1][2] Clinical Trials and Data - The EV-303 trial (KEYNOTE-905) will evaluate enfortumab vedotin plus pembrolizumab as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer who are not eligible for cisplatin-based chemotherapy [3][4] - Long-term follow-up data from the EV-302 trial will explore the utility of enfortumab vedotin in patients with challenging baseline characteristics, including older patients and those with comorbidities [3][4] - The EMBARK trial will present final data assessing overall survival with enzalutamide in combination with leuprolide and as monotherapy in patients with non-metastatic hormone-sensitive prostate cancer [3][4] Innovative Treatments - Astellas is advancing its investigational bispecific T cell engager ASP2138, targeting CLDN18.2 in solid tumors, with initial clinical data being presented [2][3][5] - The company continues to explore treatment options for gastric and gastroesophageal junction cancers with new clinical data for ASP2138 [2][5]